NCT06896422RecruitingPhase 1
Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
Prospective, Randomized Controlled Clinical Trial of Glutathione Combined With PD-1 Antibody and Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 7 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Chemotherapeutic agents exert significant immunomodulatory effects by influencing tumor-infiltrating immune cells. However, the sequence and combination of chemotherapy regimens differentially modulate immune cell dynamics, ultimately impacting treatment efficacy and patient survival. Glutathione, a critical bioactive molecule, demonstrates broad potential in tumor immunotherapy. Through mechanisms such as scavenging free radicals, modulating immune cell proliferation and differentiation, and regulating cytokine expression, glutathione achieves precise modulation of immune responses to enhance immune system functionality. To investigate whether glutathione can enhance the clinical efficacy of current chemo-immunotherapy regimens in non-small cell lung cancer (NSCLC), investigators conducted this clinical study.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 20 Mar 2025
- Start date
- 1 Jun 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- The First Affiliated Hospital of Zhengzhou University
- Diseases
- Lung cancer
- NCT number
- NCT06896422
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 80
- From 1 Jun 2025 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with small cell lung cancer or other histological subtypes of lung cancer.
Other
- Patients lost to follow-up, who discontinued treatment, or died within one year of diagnosis.
- Pregnant or lactating women
Who the study is looking for
- Histologically or cytologically confirmed diagnosis of lung squamous cell carcinoma or adenocarcinoma.
- Documented disease progression following first-line chemotherapy or chemo-immunotherapy.
- Age ≥18 years at the time of enrollment.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Zhengzhou University Coordinator of this site? Confirm its status | Zhengzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.